Oh gosh, solid RED selling?
OCAT listing on the Nasdaq apparently hasn't solved all their problems I guess?
They'll still more than likely need to do a very large share dilution too, as they don't have anywhere near the funds to conduct the promised large, phase II trial. As of now they're simply living off of and keeping the lights on and door open using Lincoln for survival- but that's not serious FDA trial kind of money IMO. Also, Lincoln in and of itself is dilutive, on-going.
If this is the relatively dilution-free version on the Nasdaq, I wonder what happens if they do a large dilution deal? They're gonna need a boat load of money- and it's gonna have to come from somewhere?
Looking pretty weak in here for the big "debut" on the Nasdaq? Not sure what's creating the selling- but the buyers seem to be in short supply so far?
